CONFERENCE DAY TWO

8:00 am Morning Coffee

8:50 am Chair’s Opening Remarks

• Jun Qi Assistant Professor – Medicine, Dana-Farber Cancer Institute

Exploring the Versatility of Induced Proximity Drugs in Post Translational Modifications Offering Novel Opportunities for Therapeutic Intervention

9:00 am PHICS: Pioneering Precision in Protein Phosphorylation Modulation

• Moses Moustakim Senior Scientist - Chemistry, Photys Therapeutics

9:30 am Developing Induced Proximity Drugs with ADCs to Demonstrate Improved Potency & Selectivity Profiles

• Thomas Pillow Senior Scientist, Genentech

10:00 am Application of Technology Platforms for Mechanism of Action Discovery

• Heidi Greulich Senior Group Leader, The Broad Institute of MIT & Harvard

10:30 am Morning Networking Break & Scientific Poster Session

Expanding Targeted Protein Degradation Beyond PROTACs with Unique Mechanisms of Action to Unlock Novel Druggable Targets

11:30 am Showcasing the EpiTAC Platform to Optimizing the Clearance of Membrane & Extracellular Targets

• Shyra Gardai Chief Scientific Officer, EpiBiologics

12:00 pm Leveraging Cryo-EM & AI for Discovery of Molecular Glues

• Sriram Subramaniam Chief Executive Officer & Founder, Gandeeva Therapeutics

12:30 pm Reviewing the Induced Proximity Landscape to Spark Novel & Continued Opportunities for Therapeutic Intervention

• Katie Spooner Research Analyst, Beacon

1:00 pm Round Table: Overcoming Challenges in Structural profiling to Reveal Ternary Complexes & Elucidate the Mechanisms of Action of Novel Induced Proximity Modalities

• Lokesh Gakhar Senior Director & Head of Structural Biology & Protein Sciences, PAQ Therapeutics

1:30 pm Networking Lunch Break

Examining Pre-Clinical & Translational Cases to Inform the Strategy for Progressing Emerging Induced Proximity Compunds into the Clinic

2:30 pm Unlocking GPCRs & Ion Channels to Antibody Pharmacology via Chemically Induced Proximity

• Brandon Turunen Co-Founder & Chief Technology Officer, Solu Therapeutics

3:00 pm Fireside Chat: Interrogating Delivery & Formulation Strategies to Improve the Development of Orally Bioavailable Compounds with Optimal Dosing & Administration Regimes

• Edmund Graziani Chief Executive Officer & Co-Founder, Apertor Pharmaceuticals
• Thomas Pillow Senior Scientist, Genentech

3:30 pm Advancing Small Molecules Targeting Autophagy Receptors into Preclinical Development to Address Unmet Patient Need in CNS Diseases

• Changhoon Ji Executive Director, AUTOTAC Bio

4:00 pm Chairs Closing Remarks & End of 4th Annual Induced Proximity Drug Discovery Summit